611例乳腺叶肿瘤患者的临床特征、预后因素和治疗结果:台湾一家机构的经验

Chun-Yueh Lin, P. Yang, Yuan-Ching Chang, W. Ko, H. Lam, Pao-Shu Wu
{"title":"611例乳腺叶肿瘤患者的临床特征、预后因素和治疗结果:台湾一家机构的经验","authors":"Chun-Yueh Lin, P. Yang, Yuan-Ching Chang, W. Ko, H. Lam, Pao-Shu Wu","doi":"10.4103/jcrp.jcrp_27_21","DOIUrl":null,"url":null,"abstract":"Background: Phyllodes tumors are uncommon biphasic breast tumors for which clinical findings remain insufficient to determine the optimal management strategy. The aim of this study was to report our experience of the clinicopathological features, prognostic factors, surgical treatment, and outcomes of patients presenting with phyllodes tumors in two different periods. Materials and Methods: We retrospectively reviewed the clinical and pathological data of 611 patients with histologically proven phyllodes tumors. The patients were separated into two groups: Period A, those who were treated from January 2006 to August 2013, and period B, those who were treated from September 2013 to September 2019. Clinical characteristics, histopathologic parameters, and outcomes were collected from patient records, and parameters were compared between the two periods. Results: The median follow-up was 7 months (range 0.5–84) in treatment period A and 14 months (range 0.5–118) in treatment period B. The median age was 38 years (range 12–75) in treatment period A and 40 years (range 12–79) in treatment period B. Analysis of the two treatment periods revealed an increase in tumor size at the diagnosis from 3.6 cm during period A to 4.5 cm during period B (P = 0.001). Most tumors were found in the upper outer quadrant, with an equal propensity to occur in either breast (34.6% vs. 42.2%). The pathologic diagnoses included 419 benign, 97 borderline, and 40 malignant lesions. Sixty cases (20 in period A and 40 in period B) experienced recurrence after surgery, including 35 benign phyllodes tumors (43% vs. 57%), 16 borderline tumors (38% vs. 63%), and 9 malignant tumors (44% vs. 56%) in either period (P = 0.003). Three cases (0.5%) (1 in period A and 2 in period B) had pulmonary metastases (0.3% vs. 0.7%). Multivariable linear regression analysis revealed that tumor size and a positive or undetermined surgical margin were the independent predictors of recurrence (P = 0.006, 0.020, and 0.004, respectively). Conclusion: Breast-conserving surgery with clear margins is technically feasible and a safe treatment for phyllodes tumors, but this strategy does not effectively further reduce local recurrence. Our findings demonstrated that clinical characteristics, tumor size, surgical margin, and pathologic features are the important predictors for tumor recurrence in patients with phyllodes tumors.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"9 1","pages":"11 - 21"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical features, prognostic factors, and treatment outcomes in 611 patients with phyllodes tumors of the breast: The experience of a single institution in Taiwan\",\"authors\":\"Chun-Yueh Lin, P. Yang, Yuan-Ching Chang, W. Ko, H. Lam, Pao-Shu Wu\",\"doi\":\"10.4103/jcrp.jcrp_27_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Phyllodes tumors are uncommon biphasic breast tumors for which clinical findings remain insufficient to determine the optimal management strategy. The aim of this study was to report our experience of the clinicopathological features, prognostic factors, surgical treatment, and outcomes of patients presenting with phyllodes tumors in two different periods. Materials and Methods: We retrospectively reviewed the clinical and pathological data of 611 patients with histologically proven phyllodes tumors. The patients were separated into two groups: Period A, those who were treated from January 2006 to August 2013, and period B, those who were treated from September 2013 to September 2019. Clinical characteristics, histopathologic parameters, and outcomes were collected from patient records, and parameters were compared between the two periods. Results: The median follow-up was 7 months (range 0.5–84) in treatment period A and 14 months (range 0.5–118) in treatment period B. The median age was 38 years (range 12–75) in treatment period A and 40 years (range 12–79) in treatment period B. Analysis of the two treatment periods revealed an increase in tumor size at the diagnosis from 3.6 cm during period A to 4.5 cm during period B (P = 0.001). Most tumors were found in the upper outer quadrant, with an equal propensity to occur in either breast (34.6% vs. 42.2%). The pathologic diagnoses included 419 benign, 97 borderline, and 40 malignant lesions. Sixty cases (20 in period A and 40 in period B) experienced recurrence after surgery, including 35 benign phyllodes tumors (43% vs. 57%), 16 borderline tumors (38% vs. 63%), and 9 malignant tumors (44% vs. 56%) in either period (P = 0.003). Three cases (0.5%) (1 in period A and 2 in period B) had pulmonary metastases (0.3% vs. 0.7%). Multivariable linear regression analysis revealed that tumor size and a positive or undetermined surgical margin were the independent predictors of recurrence (P = 0.006, 0.020, and 0.004, respectively). Conclusion: Breast-conserving surgery with clear margins is technically feasible and a safe treatment for phyllodes tumors, but this strategy does not effectively further reduce local recurrence. Our findings demonstrated that clinical characteristics, tumor size, surgical margin, and pathologic features are the important predictors for tumor recurrence in patients with phyllodes tumors.\",\"PeriodicalId\":31219,\"journal\":{\"name\":\"Journal of Cancer Research and Practice\",\"volume\":\"9 1\",\"pages\":\"11 - 21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrp.jcrp_27_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrp.jcrp_27_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:叶状瘤是一种罕见的双期乳腺肿瘤,临床表现尚不足以确定最佳治疗策略。本研究的目的是报告我们的临床病理特征,预后因素,手术治疗的经验,以及在两个不同时期出现叶状瘤的患者的结果。材料与方法:回顾性分析611例经组织学证实的叶状肿瘤的临床和病理资料。患者分为两组:A期患者于2006年1月至2013年8月接受治疗;B期患者于2013年9月至2019年9月接受治疗。从患者记录中收集临床特征、组织病理学参数和结果,并比较两个时期的参数。结果:A治疗期中位随访时间为7个月(0.5 ~ 84个月),B治疗期中位随访时间为14个月(0.5 ~ 118个月)。A治疗期中位年龄为38岁(12 ~ 75岁),B治疗期中位年龄为40岁(12 ~ 79岁)。两个治疗期的分析显示,诊断时肿瘤大小从A治疗期的3.6 cm增加到B治疗期的4.5 cm (P = 0.001)。大多数肿瘤位于上外侧象限,双侧发生率相等(34.6%对42.2%)。病理诊断为良性病变419例,交界性病变97例,恶性病变40例。术后复发60例(A期20例,B期40例),其中良性叶状肿瘤35例(43%比57%),交界性肿瘤16例(38%比63%),恶性肿瘤9例(44%比56%)(P = 0.003)。3例(0.5%)(A期1例,B期2例)发生肺转移(0.3% vs 0.7%)。多变量线性回归分析显示,肿瘤大小和阳性或未确定的手术切缘是复发的独立预测因素(P分别为0.006、0.020和0.004)。结论:保乳清缘手术治疗叶状肿瘤在技术上是可行且安全的,但不能有效地进一步减少局部复发。我们的研究结果表明,临床特征、肿瘤大小、手术切缘和病理特征是预测分叶状肿瘤复发的重要因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical features, prognostic factors, and treatment outcomes in 611 patients with phyllodes tumors of the breast: The experience of a single institution in Taiwan
Background: Phyllodes tumors are uncommon biphasic breast tumors for which clinical findings remain insufficient to determine the optimal management strategy. The aim of this study was to report our experience of the clinicopathological features, prognostic factors, surgical treatment, and outcomes of patients presenting with phyllodes tumors in two different periods. Materials and Methods: We retrospectively reviewed the clinical and pathological data of 611 patients with histologically proven phyllodes tumors. The patients were separated into two groups: Period A, those who were treated from January 2006 to August 2013, and period B, those who were treated from September 2013 to September 2019. Clinical characteristics, histopathologic parameters, and outcomes were collected from patient records, and parameters were compared between the two periods. Results: The median follow-up was 7 months (range 0.5–84) in treatment period A and 14 months (range 0.5–118) in treatment period B. The median age was 38 years (range 12–75) in treatment period A and 40 years (range 12–79) in treatment period B. Analysis of the two treatment periods revealed an increase in tumor size at the diagnosis from 3.6 cm during period A to 4.5 cm during period B (P = 0.001). Most tumors were found in the upper outer quadrant, with an equal propensity to occur in either breast (34.6% vs. 42.2%). The pathologic diagnoses included 419 benign, 97 borderline, and 40 malignant lesions. Sixty cases (20 in period A and 40 in period B) experienced recurrence after surgery, including 35 benign phyllodes tumors (43% vs. 57%), 16 borderline tumors (38% vs. 63%), and 9 malignant tumors (44% vs. 56%) in either period (P = 0.003). Three cases (0.5%) (1 in period A and 2 in period B) had pulmonary metastases (0.3% vs. 0.7%). Multivariable linear regression analysis revealed that tumor size and a positive or undetermined surgical margin were the independent predictors of recurrence (P = 0.006, 0.020, and 0.004, respectively). Conclusion: Breast-conserving surgery with clear margins is technically feasible and a safe treatment for phyllodes tumors, but this strategy does not effectively further reduce local recurrence. Our findings demonstrated that clinical characteristics, tumor size, surgical margin, and pathologic features are the important predictors for tumor recurrence in patients with phyllodes tumors.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
24 weeks
期刊介绍: JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.
期刊最新文献
Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology A juvenile female with ductal carcinoma In situ arising from a fibroadenoma Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies Promising response with PI3K inhibitor for a patient with heavily pretreated PIK3CA mutation head-and-neck cancer Significance of baseline and changes of tumor markers and neutrophil-to-lymphocyte ratio in predicting overall survival for patients with advanced pancreatic adenocarcinoma: A retrospective analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1